MIT researchers have developed a gold nanoparticle device embedded in a hydrogel that can be injected or implanted at a tumor site to disrupt cancer genes.
The nanodevice blocks the gene that confers drug resistance, then launches a new chemotherapy attack against the vulnerable tumor.
Nuria Oliva, Natalie Artzi, and Joao Conde tested the device in mice implanted with a triple negative breast tumor. It blocked the gene for multidrug resistant protein 1 and then delivered the chemotherapy drug 5-fluorouracil. The tumors shrunk by 90 percent in two weeks.
Wearable Tech + Digital Health NYC 2015 – June 30 @ New York Academy of Sciences